NCT06456528

QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia

Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia.

• Status: Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 235 (estimated)
• Sponsor: Qilu Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of QL0911 in cancer treatment-induced thrombocytopenia. Thrombocytopenia is a low number of platelets in the blood. Sometimes, thrombocytopenia is a side effect of cancer treatment.

Conditions

• Cancer Treatment-Induced Thrombocytopenia

Interventions

Type	Name	Description
DRUG	QL0911	QL0911
DRUG	QL0911 plus Placebo	QL0911 plus Placebo
DRUG	Placebo	Placebo

Timeline

• Start date: 2024-10-22
• Primary completion: 2026-07-01
• Completion: 2026-12-01
• First posted: 2024-06-13
• Last updated: 2026-01-12

Locations

2 sites across 1 country: China